Skip to content
Main Navigation
Aveo Oncology Logo
  • About
  • Partnerships
  • Our Science
  • Medical Information
  • Newsroom
  • Contact
    • About
      • Culture
      • Management Team
      • Careers
      • Compliance and Ethics
      Partnerships
      • Scientific Advisory Committee
      Our Science
      • FOTIVDA
      • Ficlatuzumab
      • Rilogrotug
      • Patents
      Medical Information
      • Publications & Presentations
      • Medical Grants – IST
      • Medical Grants – CME
      • Expanded Access Policy
      Newsroom
      Contact
  • About
    • Culture
    • Management Team
    • Careers
    • Compliance and Ethics
  • Partnerships
    • Scientific Advisory Committee
  • Our Science
    • FOTIVDA
    • Ficlatuzumab
    • Rilogrotug
    • Patents
  • Medical Information
    • Publications & Presentations
    • Medical Grants – IST
    • Medical Grants – CME
    • Expanded Access Policy
  • Newsroom
  • Contact

Tag: Rilogrotug

Cancer cachexia marker, Growth Differentiation Factor 15 (GDF-15), serum level mapping in real world samples from patients with pancreatic (PANC) or colorectal cancer (CRC)

Posted on October 22, 2025 (November 21, 2025) by michael

Cancer cachexia marker, Growth Differentiation Factor 15 (GDF-15), serum level mapping in real world samples from patients with pancreatic (PANC) or colorectal cancer (CRC)

Posted in PresentationTagged Rilogrotug

A Phase 1b Dose Escalation Study of AV-380 (Anti-GDF15 Monoclonal Antibody) in Combination with Standard-of-Care Therapy in Cancer Patients with Cachexia

Posted on May 30, 2025 (November 21, 2025) by michael

A Phase 1b Dose Escalation Study of AV-380 (Anti-GDF15 Monoclonal Antibody) in Combination with Standard-of-Care Therapy in Cancer Patients with Cachexia

Posted in PresentationTagged Rilogrotug

CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels

Posted on September 28, 2023 (December 10, 2024) by michael

CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels

Posted in PresentationTagged Rilogrotug
  • Careers
  • Terms of Use
  • Privacy Policy
  • LG Chem
  • Code of Business Conduct and Ethics

Copyright © 2025 AVEO Pharmaceuticals, Inc. All rights reserved.